Pathogens Resistant to Antibacterial Agents

Infectious Disease Clinics of North America

Volumn 23, Issue 4, 2009, Pages 817-845

  Chen, Luke F ^a   Chopra, Teena ^b   Kaye, Keith S ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter baumanii; Drug resistance; Extended spectrum lactamase; Klebsiella pneumoniae carbapenemase; Methicillin resistant Staphylococcus aureus; Penicillin resistant Streptococcus pneumoniae; Vancomycin intermediate susceptible Staphylococcus aureus; Vancomycin resistant Enterococcus

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DAPTOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN BINDING PROTEIN 2A; PENICILLIN G; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL MUTATION; CAMPYLOBACTER JEJUNI; ENTEROCOCCUS; ENZYME INACTIVATION; ENZYME SYNTHESIS; ESCHERICHIA COLI; GENE EXPRESSION; GENETIC RESISTANCE; GENOTYPE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PENICILLIN RESISTANCE; REVIEW; SALMONELLA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; TYPHOID FEVER; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; KLEBSIELLA PNEUMONIAE;

EID: 71049190564     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.06.002     Document Type: Review

References (196)

1. Neu H.C. The crisis in antibiotic resistance. [see comments]. Science 257 5073 (1992) 1064-1073
2. Nikaido H. Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin Cell Dev Biol 12 3 (2001) 215-223
3. Davies J., and Wright G.D. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 5 6 (1997) 234-240
4. Helfand M.S., and Bonomo R.A. Beta-lactamases: a survey of protein diversity. Curr Drug Targets Infect Disord 3 1 (2003) 9-23
5. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 264 5157 (1994) 375-382
6. Spratt B.G. Resistance to antibiotics mediated by target alterations. Science 264 5157 (1994) 388-393
7. Fraimow H., and Courvalin P. Resistance to glycopeptides in gram-positive pathogens. In: Novick R., Fischetti V., Feretti J., et al. (Eds). Gram positive pathogens (2000), ASM Press, Washington, DC 621-634
8. Normark B.H., and Normark S. Evolution and spread of antibiotic resistance. J Intern Med 252 2 (2002) 91-106
9. Courvalin P. Transfer of antibiotic resistance genes between gram-positive and gram- negative bacteria. Antimicrob Agents Chemother 38 7 (1994) 1447-1451
10. Moellering RC Jr. Therapeutic options for infections caused by multiply-resistant enterococci. Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Orlando (FL); 4-7 October, 1994.
11. Murray B.E., Singh K.V., Markowitz S.M., et al. Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis 163 4 (1991) 780-785
12. Grayson M.L., Eliopoulos G.M., Wennersten C.B., et al. Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother 35 11 (1991) 2180-2184
13. Boyce J.M., Opal S.M., Potter-Bynoe G., et al. Emergence and nosocomial transmission of ampicillin-resistant enterococci. Antimicrob Agents Chemother 36 5 (1992) 1032-1039
14. Williamson R., le Bouguenec C., Gutmann L., et al. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin. J Gen Microbiol 131 8 (1985) 1933-1940
15. Rupp M.E., Marion N., Fey P.D., et al. Outbreak of vancomycin-resistant Enterococcus faecium in a neonatal intensive care unit. Infect Control Hosp Epidemiol 22 5 (2001) 301-303
16. Patterson J.E., and Zervos M.J. High-level gentamicin resistance in Enterococcus: microbiology, genetic basis, and epidemiology. Rev Infect Dis 12 4 (1990) 644-652
17. Krogstad D.J., Korfhagen T.R., Moellering Jr. R.C., et al. Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis: an explanation for resistance to antibiotic synergism. J Clin Invest 62 2 (1978) 480-486
18. Hidron A.I., Edwards J.R., Patel J., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29 11 (2008) 996-1011
19. Mutnick A.H., Biedenbach D.J., and Jones R.N. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 46 1 (2003) 63-68
20. Livornese Jr. L.L., Dias S., Samel C., et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 117 2 (1992) 112-116
21. Carmeli Y., Eliopoulos G.M., and Samore M.H. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 8 8 (2002) 802-807
22. Arthur M., and Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 37 8 (1993) 1563-1571
23. Shlaes D.M., Etter L., and Gutmann L. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother 35 4 (1991) 776-779
24. Power E.G., Abdulla Y.H., Talsania H.G., et al. vanA genes in vancomycin-resistant clinical isolates of Oerskovia turbata and Arcanobacterium (Corynebacterium) haemolyticum. J Antimicrob Chemother 36 4 (1995) 595-606
25. Ligozzi M., Lo Cascio G., and Fontana R. vanA gene cluster in a vancomycin-resistant clinical isolate of Bacillus circulans. Antimicrob Agents Chemother 42 8 (1998) 2055-2059
26. Mevius D., Devriese L., Butaye P., et al. Isolation of glycopeptide resistant Streptococcus gallolyticus strains with vanA, vanB, and both vanA and vanB genotypes from faecal samples of veal calves in The Netherlands. J Antimicrob Chemother 42 2 (1998) 275-276
27. Dutka-Malen S., Blaimont B., Wauters G., et al. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother 38 7 (1994) 1675-1677
28. Centers for Disease Control and Prevention (CDC) Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 51 26 (2002) 565-567
29. Noble W.C., Virani Z., and Cree R.G. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 72 2 (1992) 195-198
30. Perichon B., Reynolds P., and Courvalin P. VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother 41 9 (1997) 2016-2018
31. McKessar S.J., Berry A.M., Bell J.M., et al. Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob Agents Chemother 44 11 (2000) 3224-3228
32. Fines M., Perichon B., Reynolds P., et al. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother 43 9 (1999) 2161-2164
33. Prystowsky J., Siddiqui F., Chosay J., et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 45 (2001) 2154-2156
34. Bonora M.G., Solbiati M., Stepan E., et al. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 44 3 (2006) 1153-1155
35. Pogue J.M., Paterson D.L., Pasculle A.W., et al. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 28 12 (2007) 1382-1388
36. Montero C.I., Stock F., and Murray P.R. Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob Agents Chemother 52 3 (2008) 1167-1170
37. Kirby W.M. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 99 2579 (1944) 452-453
38. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing (2008), Clinical and Laboratory Standards Institute (CLSI), Wayne (PA)
39. Sievert D.M., Rudrik J.T., Patel J.B., et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46 5 (2008) 668-674
40. Cunha B.A., Mikail N., and Eisenstein L. Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia due to a linezolid tolerant strain. Heart Lung 37 5 (2008) 398-400
41. Murthy M.H., Olson M.E., Wickert R.W., et al. Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol 57 Pt 8 (2008) 1036-1038
42. Higuchi W., Takano T., Teng L.J., et al. Structure and specific detection of staphylococcal cassette chromosome mec type VII. Biochem Biophys Res Commun 377 3 (2008) 752-756
43. Oliveira D.C., Milheirico C., and de Lencastre H. Redefining a structural variant of staphylococcal cassette chromosome mec, SCCmec type VI. Antimicrob Agents Chemother 50 10 (2006) 3457-3459
44. Zhang K., McClure J.A., Elsayed S., et al. Novel staphylococcal cassette chromosome mec type carrying class A mec and type 4 ccr gene complexes in a Canadian epidemic strain of methicillin-resistant Staphylococcus aureus 53 2 (2009) 531-540
45. Katayama Y., Ito T., and Hiramatsu K. Genetic organization of the chromosome region surrounding mecA in clinical staphylococcal strains: role of IS431-mediated mecI deletion in expression of resistance in mecA-carrying, low-level methicillin-resistant Staphylococcus haemolyticus. Antimicrob Agents Chemother 45 7 (2001) 1955-1963
46. Boyle-Vavra S., and Daum R.S. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 87 1 (2007) 3-9
47. Martinez-Aguilar G., Hammerman W.A., Mason Jr. E.O., et al. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 22 7 (2003) 593-598
48. Weigel L.M., Clewell D.B., Gill S.R., et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302 5650 (2003) 1569-1571
49. Reynolds P.E., and Courvalin P. Vancomycin resistance in enterococci due to synthesis of precursors terminating in D-alanyl-D-serine. Antimicrob Agents Chemother 49 1 (2005) 21-25
50. Soriano A., Marco F., Martinez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46 2 (2008) 193-200
51. Sakoulas G., Moise-Broder P.A., Schentag J., et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 6 (2004) 2398-2402
52. Steinkraus G., White R., and Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 60 4 (2007) 788-794
53. Alos J.I., Garcia-Canas A., Garcia-Hierro P., et al. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 62 4 (2008) 773-775
54. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42 Suppl 1 (2006) S13-S24
55. Wang G., Hindler J.F., Ward K.W., et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44 11 (2006) 3883-3886
56. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66 1 (2009) 82-98
57. Champney W.S., and Miller M. Linezolid is a specific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol 44 5 (2002) 350-356
58. Tsiodras S., Gold H.S., Sakoulas G., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 9277 (2001) 207-208
59. Besier S., Ludwig A., Zander J., et al. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob Agents Chemother 52 4 (2008) 1570-1572
60. Silverman J.A., Perlmutter N.G., and Shapiro H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47 8 (2003) 2538-2544
61. Silverman J.A., Mortin L.I., Vanpraagh A.D., et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 12 (2005) 2149-2152
62. Skiest D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44 2 (2006) 655-656
63. Sakoulas G., Alder J., Thauvin-Eliopoulos C., et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50 4 (2006) 1581-1585
64. Jones T., Yeaman M.R., Sakoulas G., et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52 1 (2008) 269-278
65. Cui L., Tominaga E., Neoh H.M., et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50 3 (2006) 1079-1082
66. Schmitz F.J., Witte W., Werner G., et al. Characterization of the translational attenuator of 20 methicillin-resistant, quinupristin/dalfopristin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides. J Antimicrob Chemother 48 6 (2001) 939-941
67. Drago L., Nicola L., and De Vecchi E. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp. Clin Microbiol Infect 14 6 (2008) 608-611
68. Allignet J., and el Solh N. Diversity among the gram-positive acetyltransferases inactivating streptogramin A and structurally related compounds and characterization of a new staphylococcal determinant, vatB. Antimicrob Agents Chemother 39 9 (1995) 2027-2036
69. Markiewicz Z., and Tomasz A. Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci. J Clin Microbiol 27 3 (1989) 405-410
70. Nagai K., Davies T.A., Jacobs M.R., et al. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother 46 5 (2002) 1273-1280
71. Zapun A., Contreras-Martel C., and Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev 32 2 (2008) 361-385
72. Pernot L., Chesnel L., Le Gouellec A., et al. A PBP2x from a clinical isolate of Streptococcus pneumoniae exhibits an alternative mechanism for reduction of susceptibility to beta-lactam antibiotics. J Biol Chem 279 16 (2004) 16463-16470
73. Sahm D.F., Brown N.P., Draghi D.C., et al. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med 120 3 Suppl 1 (2008) 8-15
74. Chiu C.H., Su L.H., Huang Y.C., et al. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrob Agents Chemother 51 9 (2007) 3404-3406
75. Gums J.G., Boatwright D.W., Camblin M., et al. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. Ann Pharmacother 42 1 (2008) 71-79
76. Cardoso M.R., Nascimento-Carvalho C.M., Ferrero F., et al. Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia. Arch Dis Child 93 3 (2008) 221-225
77. Sahm D.F., Brown N.P., Thornsberry C., et al. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med 120 3 Suppl 1 (2008) 16-24
78. Rodriguez C.A., Atkinson R., Bitar W., et al. Tolerance to vancomycin in pneumococci: detection with a molecular marker and assessment of clinical impact. J Infect Dis 190 8 (2004) 1481-1487
79. Low D.E. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin Infect Dis 38 Suppl 4 (2004) S357-S362
80. Sirot D.L., Goldstein F.W., Soussy C.J., et al. Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France. Antimicrob Agents Chemother 36 8 (1992) 1677-1681
81. Burwen D.R., Banerjee S.N., and Gaynes R.P. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis 170 6 (1994) 1622-1625
82. Edwards J.R., Peterson K.D., Andrus M.L., et al. National Healthcare Safety Network (NHSN) Report, data summary for 2006 through 2007, issued November 2008. Am J Infect Control 36 9 (2008) 609-626
83. Jacoby G.A. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. Infect Dis Clin North Am 11 4 (1997) 875-887
84. Wiener J., Quinn J.P., Bradford P.A., et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. [see comments]. JAMA 281 6 (1999) 517-523
85. Montgomerie J.Z. Epidemiology of Klebsiella and hospital-associated infections. Rev Infect Dis 1 5 (1979) 736-753
86. Lin M.F., Huang M.L., and Lai S.H. Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. J Hosp Infect 53 1 (2003) 39-45
87. Lautenbach E., Patel J.B., Bilker W.B., et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32 8 (2001) 1162-1171
88. Du B., Long Y., Liu H., et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 28 12 (2002) 1718-1723
89. D'Agata E., Venkataraman L., DeGirolami P., et al. The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital. J Infect 36 3 (1998) 279-285
90. Rahal J.J., Urban C., Horn D., et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. [see comments]. JAMA 280 14 (1998) 1233-1237
91. Pena C., Pujol M., Ardanuy C., et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 42 1 (1998) 53-58
92. Harris A.D., McGregor J.C., Johnson J.A., et al. Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 13 8 (2007) 1144-1149
93. Amino acid sequences for TEM, SHV and OXA extended-spectrum beta-lactamases. Available at:. http://www.lahey.org/studies/inc_webt.asp Accessed July, 2009
94. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48 1 (2004) 1-14
95. Livermore D.M. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8 4 (1995) 557-584
96. Nordmann P., and Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect 8 6 (2002) 321-331
97. Patel G., Huprikar S., Factor S.H., et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29 12 (2008) 1099-1106
98. Martinez-Martinez L., Hernandez-Alles S., Alberti S., et al. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemother 40 2 (1996) 342-348
99. Pangon B., Bizet C., Bure A., et al. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis 159 5 (1989) 1005-1006
100. Kaye K.S., Gold H.S., Schwaber M.J., et al. Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States. Antimicrob Agents Chemother 48 5 (2004) 1520-1525
101. Coudron P.E., Moland E.S., and Thomson K.S. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol 38 5 (2000) 1791-1796
102. Bell J.M., Turnidge J.D., Gales A.C., et al. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 42 3 (2002) 193-198
103. Andriole V.T. The quinolones. 2nd edition (1998), Academic Press, New York
104. Mandell G.L., Bennett J.E., and Mandell D.R. Douglas and Bennett's principles and practice of infectious diseases. 6th edition (2004), Churchill Livingstone, New York
105. Anthony K.B., Fishman N.O., Linkin D.R., et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 46 4 (2008) 567-570
106. Yang K., and Guglielmo B.J. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother 41 9 (2007) 1427-1435
107. Sanders Jr. W.E., and Sanders C.C. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 10 4 (1988) 830-838
108. Tenover F.C., Emery S.L., Spiegel C.A., et al. Identification of plasmid-mediated AmpC {beta}-lactamases in Escherichia coli, Klebsiella pneumoniae, and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J Clin Microbiol 47 2 (2009) 294-299
109. Fakioglu E., Queenan A.M., Bush K., et al. Amp C beta-lactamase-producing Escherichia coli in neonatal meningitis: diagnostic and therapeutic challenge. J Perinatol 26 8 (2006) 515-517
110. Jacobs C., Frere J.M., and Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria. Cell 88 6 (1997) 823-832
111. Korsak D., Liebscher S., and Vollmer W. Susceptibility to antibiotics and beta-lactamase induction in murein hydrolase mutants of Escherichia coli. Antimicrob Agents Chemother 49 4 (2005) 1404-1409
112. Medeiros A.A. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 24 Suppl 1 (1997) S19-S45
113. Kaye K.S., Cosgrove S., Harris A., et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 45 9 (2001) 2628-2630
114. Mammeri H., Poirel L., Bemer P., et al. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC beta-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother 48 3 (2004) 716-720
115. Ceccarelli M., and Ruggerone P. Physical insights into permeation of and resistance to antibiotics in bacteria. Curr Drug Targets 9 9 (2008) 779-788
116. Kessler R.E. Cefepime microbiologic profile and update. Pediatr Infect Dis J 20 3 (2001) 331-336
117. Ishii Y., Tateda K., and Yamaguchi K. Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006). Diagn Microbiol Infect Dis 60 2 (2008) 177-183
118. Poirel L., Pitout J.D., and Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol 2 5 (2007) 501-512
119. Yigit H., Queenan A.M., Anderson G.J., et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45 4 (2001) 1151-1161
120. Bratu S., Brooks S., Burney S., et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 44 7 (2007) 972-975
121. Lomaestro B.M., Tobin E.H., Shang W., et al. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 43 3 (2006) e26-e28
122. Bratu S., Mooty M., Nichani S., et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 49 7 (2005) 3018-3020
123. Miriagou V., Tzouvelekis L.S., Rossiter S., et al. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 47 4 (2003) 1297-1300
124. Villegas M.V., Lolans K., Correa A., et al. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 51 4 (2007) 1553-1555
125. Peleg A.Y., Franklin C., Bell J.M., et al. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 41 11 (2005) 1549-1556
126. Lolans K., Rice T.W., Munoz-Price L.S., et al. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 50 9 (2006) 2941-2945
127. Danes C., Navia M.M., Ruiz J., et al. Distribution of beta-lactamases in Acinetobacter baumannii clinical isolates and the effect of Syn 2190 (AmpC inhibitor) on the MICs of different beta-lactam antibiotics. J Antimicrob Chemother 50 2 (2002) 261-264
128. Livermore D.M. Acquired carbapenemases. J Antimicrob Chemother 39 6 (1997) 673-676
129. Afzal-Shah M., Woodford N., and Livermore D.M. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 45 2 (2001) 583-588
130. Bou G., Cervero G., Dominguez M.A., et al. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol 38 9 (2000) 3299-3305
131. Quale J., Bratu S., Landman D., et al. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 37 2 (2003) 214-220
132. Perez F., Hujer A.M., Hujer K.M., et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51 10 (2007) 3471-3484
133. Miller G.H., Sabatelli F.J., Hare R.S., et al. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 24 Suppl 1 (1997) S46-S62
134. Vila J., Ruiz J., Goni P., et al. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 39 6 (1997) 757-762
135. Turner P.J., and Greenhalgh J.M. The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. Clin Microbiol Infect 9 6 (2003) 563-567
136. Landman D., Quale J.M., Mayorga D., et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 162 13 (2002) 1515-1520
137. Landman D., Bratu S., Kochar S., et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 60 1 (2007) 78-82
138. Seifert H., Strate A., and Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 74 6 (1995) 340-349
139. Vila J., Ribera A., Marco F., et al. Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 49 3 (2002) 471-477
140. Maragakis L.L., and Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46 8 (2008) 1254-1263
141. Nicodemo A.C., and Paez J.I. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 26 4 (2007) 229-237
142. Denton M., and Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 11 1 (1998) 57-80
143. Avison M.B., von Heldreich C.J., Higgins C.S., et al. A TEM-2beta-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J Antimicrob Chemother 46 6 (2000) 879-884
144. Cullmann W. Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates. Chemotherapy 37 4 (1991) 246-250
145. Alonso A., and Martinez J.L. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 45 6 (2001) 1879-1881
146. Barbolla R., Catalano M., Orman B.E., et al. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 48 2 (2004) 666-669
147. Toleman M.A., Bennett P.M., Bennett D.M., et al. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 13 4 (2007) 559-565
148. Gales A.C., Jones R.N., Forward K.R., et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 32 Suppl 2 (2001) S104-S113
149. Jones R.N., Pfaller M.A., Marshall S.A., et al. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Diagn Microbiol Infect Dis 29 3 (1997) 187-192
150. Canton R., Valdezate S., Vindel A., et al. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates. Pediatr Pulmonol 35 2 (2003) 99-107
151. Insa R., Cercenado E., Goyanes M.J., et al. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 59 3 (2007) 583-585
152. Krueger T.S., Clark E.A., and Nix D.E. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 41 1-2 (2001) 71-78
153. Al-Jasser A.M. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 5 (2006) 23
154. Parry C.M., and Threlfall E.J. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 21 5 (2008) 531-538
155. Parry C.M., Hien T.T., Dougan G., et al. Typhoid fever. N Engl J Med 347 22 (2002) 1770-1782
156. Taylor D.E., Chumpitaz J.C., and Goldstein F. Variability of IncHI1 plasmids from Salmonella typhi with special reference to Peruvian plasmids encoding resistance to trimethoprim and other antibiotics. Antimicrob Agents Chemother 28 3 (1985) 452-455
157. Gilmour M.W., Thomson N.R., Sanders M., et al. The complete nucleotide sequence of the resistance plasmid R478: defining the backbone components of incompatibility group H conjugative plasmids through comparative genomics. Plasmid 52 3 (2004) 182-202
158. Capoor M.R., Nair D., Deb M., et al. Enteric fever perspective in India: emergence of high-level ciprofloxacin resistance and rising MIC to cephalosporins. J Med Microbiol 56 Pt 8 (2007) 1131-1132
159. Ko W.C., Yan J.J., Yu W.L., et al. A new therapeutic challenge for old pathogens: community-acquired invasive infections caused by ceftriaxone- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis. Clin Infect Dis 40 2 (2005) 315-318
160. Shirakawa T., Acharya B., Kinoshita S., et al. Decreased susceptibility to fluoroquinolones and gyrA gene mutation in the Salmonella enterica serovar typhi and paratyphi A isolated in Katmandu, Nepal, in 2003. Diagn Microbiol Infect Dis 54 4 (2006) 299-303
161. Crump J.A., Kretsinger K., Gay K., et al. Clinical response and outcome of infection with Salmonella enterica serotype typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study. Antimicrob Agents Chemother 52 4 (2008) 1278-1284
162. Kownhar H., Shankar E.M., Rajan R., et al. Emergence of nalidixic acid-resistant Salmonella enterica serovar typhi resistant to ciprofloxacin in India. J Med Microbiol 56 Pt 1 (2007) 136-137
163. Crump J.A., Barrett T.J., Nelson J.T., et al. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype typhi and for non-typhi salmonellae. Clin Infect Dis 37 1 (2003) 75-81
164. Su L.H., Wu T.L., Chia J.H., et al. Increasing ceftriaxone resistance in Salmonella isolates from a university hospital in Taiwan. J Antimicrob Chemother 55 6 (2005) 846-852
165. Thaver D., Zaidi A.K., Critchley J.A., et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 4 (2008) CD004530
166. Threlfall E.J., and Ward L.R. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom. Emerg Infect Dis 7 3 (2001) 448-450
167. Connor B.A., and Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 5 10 (2005) 623-628
168. Skov M.N., Andersen J.S., and Baggesen D.L. Occurrence and spread of multiresistant Salmonella typhimurium DT104 in Danish animal herds investigated by the use of DNA typing and spatio-temporal analysis. Epidemiol Infect 136 8 (2008) 1124-1130
169. Meakins S., Fisher I.S., Berghold C., et al. Antimicrobial drug resistance in human nontyphoidal Salmonella isolates in Europe 2000-2004: a report from the Enter-net International Surveillance Network. Microb Drug Resist 14 1 (2008) 31-35
170. Gay K., Robicsek A., Strahilevitz J., et al. Plasmid-mediated quinolone resistance in non-typhi serotypes of Salmonella enterica. Clin Infect Dis 43 3 (2006) 297-304
171. Li W.C., Huang F.Y., Liu C.P., et al. Ceftriaxone resistance of nontyphoidal Salmonella enterica isolates in Northern Taiwan attributable to production of CTX-M-14 and CMY-2 beta-lactamases. J Clin Microbiol 43 7 (2005) 3237-3243
172. Gupta A., Fontana J., Crowe C., et al. Emergence of multidrug-resistant Salmonella enterica serotype Newport infections resistant to expanded-spectrum cephalosporins in the United States. J Infect Dis 188 11 (2003) 1707-1716
173. Armand-Lefevre L., Leflon-Guibout V., Bredin J., et al. Imipenem resistance in Salmonella enterica serovar Wien related to porin loss and CMY-4 beta-lactamase production. Antimicrob Agents Chemother 47 3 (2003) 1165-1168
174. Shlim D.R. Update in traveler's diarrhea. Infect Dis Clin North Am 19 1 (2005) 137-149
175. Little C.L., Richardson J.F., Owen R.J., et al. Campylobacter and Salmonella in raw red meats in the United Kingdom: prevalence, characterization and antimicrobial resistance pattern, 2003-2005. Food Microbiol 25 3 (2008) 538-543
176. Ruiz J., Marco F., Oliveira I., et al. Trends in antimicrobial resistance in Campylobacter spp. causing traveler's diarrhea. APMIS 115 3 (2007) 218-224
177. Serichantalergs O., Dalsgaard A., Bodhidatta L., et al. Emerging fluoroquinolone and macrolide resistance of Campylobacter jejuni and Campylobacter coli isolates and their serotypes in Thai children from 1991 to 2000. Epidemiol Infect 135 8 (2007) 1299-1306
178. Smith K.E., Besser J.M., Hedberg C.W., et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation team. N Engl J Med 340 20 (1999) 1525-1532
179. Gibreel A., and Taylor D.E. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother 58 2 (2006) 243-255
180. Allos B.M. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 32 8 (2001) 1201-1206
181. Engberg J., Aarestrup F.M., Taylor D.E., et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 7 1 (2001) 24-34
182. Yan M., Sahin O., Lin J., et al. Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure. J Antimicrob Chemother 58 6 (2006) 1154-1159
183. Centers for Disease Control and Prevention (CDC). Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. [see comment]. MMWR Morb Mortal Wkly Rep 51 46 (2002) 1041-1044
184. Erbelding E., and Quinn T.C. The impact of antimicrobial resistance on the treatment of sexually transmitted diseases. Infect Dis Clin North Am 11 4 (1997) 889-903
185. Ropp P.A., Hu M., Olesky M., et al. Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 46 3 (2002) 769-777
186. Ison C.A., Dillon J.A., and Tapsall J.W. The epidemiology of global antibiotic resistance among Neisseria gonorrhoeae and Haemophilus ducreyi. Lancet 351 Suppl 3 (1998) 8-11 [erratum appears in Lancet 1998 Oct 17;352(9136):1316]
187. Gonococcal Isolate Surveillance Project (GISP) Annual Report (2006), Centers for Disease Control and Prevention. http://www.cdc.gov/std/GISP2006/GISPSurvSupp2006Short.pdf Accessed August 1, 2009
188. Gill M.J., Simjee S., Al-Hattawi K., et al. Gonococcal resistance to beta-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob Agents Chemother 42 11 (1998) 2799-2803
189. Galimand M., Gerbaud G., and Courvalin P. Spectinomycin resistance in Neisseria spp. due to mutations in 16S rRNA. Antimicrob Agents Chemother 44 5 (2000) 1365-1366
190. Cousin Jr. S.L., Whittington W.L., and Roberts M.C. Acquired macrolide resistance genes and the 1 bp deletion in the mtrR promoter in Neisseria gonorrhoeae. J Antimicrob Chemother 51 1 (2003) 131-133
191. Fenton K.A., Ison C., Johnson A.P., et al. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. [see comment]. Lancet 361 9372 (2003) 1867-1869
192. Anonymous. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2000. Commun Dis Intell 25 4 (2001) 274-276
193. Kam K.M., Kam S.S., Cheung D.T., et al. Molecular characterization of quinolone-resistant Neisseria gonorrhoeae in Hong Kong. Antimicrob Agents Chemother 47 1 (2003) 436-439
194. Trees D.L., Sandul A.L., Neal S.W., et al. Molecular epidemiology of Neisseria gonorrhoeae exhibiting decreased susceptibility and resistance to ciprofloxacin in Hawaii, 1991-1999. Sex Transm Dis 28 6 (2001) 309-314
195. McMurry L., Petrucci Jr. R.E., and Levy S.B. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc Natl Acad Sci U S A 77 7 (1980) 3974-3977
196. Li X.Z., and Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 64 2 (2004) 159-204